Recommendations of the Spanish Society of Paediatric Cardiology and Congenital Heart Disease as regards the use of drugs in attention deficit hyperactivity disorder in children and adolescents with a known heart disease, as well as in the general paediatric population: position statement by the Spanish Paediatric Association

Picarzo, Javier Pérez-Lescure; Malfaz, Fernándo Centeno; Marcos, D. Crespo; Hernández, Rosa Collell; Soria, T; García, Begoña Manso; Sombrero, Henar Rojo; Sabaté-Rotés, Anna; Sarquella‐Brugada, Georgia

doi:10.1016/j.anpede.2019.09.006

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T-wave inversions in leads III and V4-V6, incomplete right bundle branch block and sinus arrythmia are common in the pediatric population ( Norrish et al, 2021 ) and should not preclude the administration of ADHD medications. Premature atrial or ventricular contractions at low frequency and in the absence of cardiac disease, are also considered benign and should not prevent the initiation of ADHD pharmacological treatment ( Picarzo et al, 2020 ).…”

Section: Direct Cardiovascular Effects Of Attention-deficit Hyperacti...mentioning

confidence: 99%

The use of attention-deficit hyperactivity disorder medications in cardiac disease

et al. 2022

View full text Add to dashboard Cite

Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder with onset usually in childhood characterized by inattention, impulsivity, and hyperactivity causing a functional impairment. Untreated ADHD, or treatment delay is associated with adverse outcomes and poor quality of life. Although conservative management strategies such as behavioral and psychological interventions are important, pharmacological treatment has a strong evidence base with improved outcomes. ADHD medications are broadly divided into stimulant and non-stimulant medications. Stimulant medications are generally more effective than non-stimulants. Cardiovascular safety of ADHD medication has been a matter of debate for decades. Treatment guidelines advise the careful consideration of risks and benefits in people with cardiovascular diseases such as congenital heart disease or cardiomyopathy. Although stimulants can increase systemic blood pressure and heart rate, no significant associations were found between their use and serious cardiovascular events. Concerns regarding QT effects and attendant sudden cardiac death risks deter clinicians from initiating much-needed ADHD medications in patients with heart disease. This overly cautious approach is potentially depriving low-risk individuals from significant benefits associated with timely ADHD drug treatment. This review discusses the cardiovascular risks reportedly associated with ADHD medications, the evidence base for their safe usage in persons with established cardiovascular disease, and highlights future research directions.

show abstract

Section: Direct Cardiovascular Effects Of Attention-deficit Hyperacti...mentioning

confidence: 99%